|
|
Maxcyte inc (NASDAQ: MXCT) |
|
Price: $1.4300
$0.13 
10.000%
|
| Day's High:
| $1.4566999673843384
| Week Perf:
| 14.4 %
|
| Day's Low: |
$ 1.29 |
30 Day Perf: |
17.21 % |
| Volume (M): |
1,387,576 |
52 Wk High: |
$ 1.80 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$1.16 |
| Open: |
$1.29 |
52 Wk Low: |
$0.64 |
|
|
| Market Capitalization (Millions $) |
153 |
| Shares
Outstanding (Millions) |
107 |
| Employees |
91 |
| Revenues (TTM) (Millions $) |
31 |
| Net Income (TTM) (Millions $) |
-36 |
| Cash Flow (TTM) (Millions $) |
-9 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Maxcyte Inc. is a biotechnology company that specializes in cell engineering and flow electroporation technology. The company is focused on developing innovative solutions for drug discovery, cell and gene therapy, and biomanufacturing. Maxcyte's proprietary technology allows for high levels of transfection efficiency and cell engineering, making it an attractive option for researchers and pharmaceutical companies looking to develop new therapies and improve biomanufacturing processes. The company also offers contract development and manufacturing services, providing support to clients in the development and production of cell-based therapies. Overall, Maxcyte Inc. plays a significant role in advancing the field of cell engineering and facilitating the development of novel therapies.
Company Address: 9713 Key West Avenue Rockville 20850 MD
Company Phone Number: 944-1700 Stock Exchange / Ticker: NASDAQ MXCT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Partnership
Published Wed, Jun 11 2025 8:55 AM UTC
Revolutionizing Cellular Therapy: MaxCyte and Ori Biotech’s Game-Changing CollaborationIn the fast-paced world of biotechnological innovation, where the stakes are as high as the potential benefits, the partnership between MaxCyte and Ori Biotech emerges as a beacon of transformative potential. With the convergence of advanced platforms, cutting-edge technology, and strat...
|
| Merger and Acquisition
Published Thu, Jan 30 2025 7:00 AM UTC
MaxCyte Expands Horizons with SeQure Dx Acquisition Amidst Financial ChallengesIn a noteworthy development within the biotech sector, MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a prominent player in cell-engineering solutions, announced its acquisition of SeQure Dx, a leader in on-target and off-target editing assessment services for cell and gene therapies. The acquisition, u...
|
| Management Announcement
Published Mon, Jan 13 2025 8:05 AM UTC
MaxCyte Inc.: A Legacy of Cell Engineering with Financial Challenges AheadMaxCyte, a prominent player in the biopharmaceutical landscape and a pioneer in cell engineering, recently released its preliminary unaudited financial results for the fourth quarter and full year ending December 31, 2024. Despite two decades of innovation, the company stands at a financial crossroads,...
|
| Management Announcement
Published Wed, Nov 13 2024 1:05 PM UTC
IntroductionMaxCyte Inc. proudly commemorates 25 years of innovation in the field of cell engineering, a milestone marked by numerous advancements in cell and gene therapy since its inception in 1999. Despite its celebrated history, the company faces challenges, including a significant net loss reported for the second quarter of 2024. However, its recent strategic partnershi...
|
| Contract
Published Mon, Sep 16 2024 6:00 AM UTC
In an ambitious stride toward transforming the landscape of genetic disease treatment, MaxCyte Inc. a global leader in cell engineering and therapeutic research, has entered into a strategic platform license agreement with Kamau Therapeutics. This collaboration aims to harness MaxCyte’s sophisticated Flow Electroporation technology and ExPERT platform to bolster Kamau s pi...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.33 $ |
| Revenues (TTM) |
0.29 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.99 $
|
| Book Value |
1.49 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
341,220 |
| Net
Income per Employee (TTM) |
-391,604 |
| Receivable Turnover Ratio (TTM) |
6.22 |
| Inventory Turnover Ratio (TTM) |
0.84 |
| Asset Turnover Ratio (TTM) |
0.16 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.33 $
|
| Revenues (TTM) |
0.29 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.99 $
|
| Book Value |
1.49 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Product |
|
 106.41 % |
of total Revenue |
| License |
|
111.68 % |
of total Revenue |
| Assay and other service revenue |
|
14.65 % |
of total Revenue |
| Cell Engineering Technology Segment |
|
232.73 % |
of total Revenue |
| US |
|
154.67 % |
of total Revenue |
| Licenses |
|
78.06 % |
of total Revenue |
| |
On March 12 2024 the Maxcyte Inc provided following guidance
MaxCyte Inc, a prominent company specializing in cell-engineering technologies, recently disclosed its financial results for the fourth quarter and full year ending on December 31, 2023. The company, listed on NASDAQ as MXCT and on the London Stock Exchange as MXCT, reported positive financial performance for the period.
The company reconfirmed its projected guidance for the year 2024, emphasizing its commitment to driving advancements in the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications.
The solid financial results and reiterated guidance demonstrate MaxCyte's success in leveraging its enabling platform technologies...
|
|
|
5.53% 